EGFR-TKI in non-small cell lung cancer treatment / 国际肿瘤学杂志
Journal of International Oncology
; (12): 601-604, 2012.
Article
en Zh
| WPRIM
| ID: wpr-427642
Biblioteca responsable:
WPRO
ABSTRACT
The epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a kind of high-efficiency and low-toxicity tumor molecular targeted drugs.It becomes a research hotspot in non-small cell lung cancer (NSCLC)treatment because of its unique curative effect and well tolerance.EGFR-TKI is mainly applied to the second and third line treatment of patients with advanced NSCLC or first line treatment of EGFR mutation patients.With the development of research,the indications of EGFR-TKI expand unceasingly.The preoperative neoadjuvant therapy is likely to become a new kind of treatment mode.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Año:
2012
Tipo del documento:
Article